Argus Reiterates “Buy” Rating for Chemours Company (The) (NYSE:CC)

Chemours Company (The) (NYSE:CC)‘s stock had its “buy” rating reissued by Argus in a research note issued to investors on Thursday. They presently have a $55.00 target price on the specialty chemicals company’s stock, up from their prior target price of $50.00. Argus’ target price would suggest a potential upside of 18.69% from the company’s current price.

Several other research analysts have also commented on CC. Citigroup Inc. reaffirmed a “neutral” rating and set a $40.00 price objective (up from $34.00) on shares of Chemours Company (The) in a research note on Friday, April 14th. J P Morgan Chase & Co raised shares of Chemours Company (The) from a “neutral” rating to an “overweight” rating and lifted their price objective for the stock from $39.00 to $50.00 in a research note on Friday, May 12th. Susquehanna Bancshares Inc lifted their price objective on shares of Chemours Company (The) from $45.00 to $55.00 and gave the stock a “positive” rating in a research note on Monday, May 15th. ValuEngine raised shares of Chemours Company (The) from a “hold” rating to a “buy” rating in a research note on Friday, June 2nd. Finally, UBS AG reaffirmed a “sell” rating and set a $36.00 price objective (up from $35.00) on shares of Chemours Company (The) in a research note on Wednesday, June 14th. Two investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. Chemours Company (The) has a consensus rating of “Buy” and a consensus price target of $51.50.

Shares of Chemours Company (NYSE:CC) opened at 46.34 on Thursday. The company has a market capitalization of $8.56 billion, a price-to-earnings ratio of 30.33 and a beta of 3.63. Chemours Company has a 12-month low of $11.33 and a 12-month high of $51.51. The company’s 50-day moving average is $43.52 and its 200-day moving average is $38.05.

Chemours Company (The) (NYSE:CC) last posted its quarterly earnings data on Wednesday, August 2nd. The specialty chemicals company reported $0.87 EPS for the quarter, topping the consensus estimate of $0.85 by $0.02. The company had revenue of $1.59 billion during the quarter, compared to analyst estimates of $1.49 billion. Chemours Company (The) had a net margin of 4.96% and a return on equity of 122.97%. Chemours Company (The)’s quarterly revenue was up 14.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.27 earnings per share. Analysts predict that Chemours Company will post $3.51 EPS for the current year.

In other news, VP Erich Parker sold 4,908 shares of Chemours Company (The) stock in a transaction on Tuesday, May 16th. The stock was sold at an average price of $45.53, for a total transaction of $223,461.24. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Paul Kirsch sold 19,036 shares of Chemours Company (The) stock in a transaction on Monday, June 5th. The stock was sold at an average price of $41.42, for a total value of $788,471.12. The disclosure for this sale can be found here. 1.14% of the stock is currently owned by company insiders.

Several hedge funds have recently added to or reduced their stakes in CC. Janney Montgomery Scott LLC acquired a new stake in Chemours Company (The) during the first quarter valued at $296,000. Acadian Asset Management LLC increased its stake in Chemours Company (The) by 22.6% in the first quarter. Acadian Asset Management LLC now owns 97,679 shares of the specialty chemicals company’s stock valued at $3,760,000 after buying an additional 18,003 shares during the period. Korea Investment CORP acquired a new stake in Chemours Company (The) during the first quarter valued at $3,134,000. Sigma Planning Corp acquired a new stake in Chemours Company (The) during the first quarter valued at $2,670,000. Finally, Nationwide Fund Advisors increased its stake in Chemours Company (The) by 262.6% in the first quarter. Nationwide Fund Advisors now owns 413,027 shares of the specialty chemicals company’s stock valued at $15,902,000 after buying an additional 299,121 shares during the period. Institutional investors and hedge funds own 75.21% of the company’s stock.

Chemours Company (The) Company Profile

The Chemours Company is a provider of performance chemicals. The Company operates through three segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Titanium Technologies segment is a producer of titanium dioxide (TiO2). The Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins.